Posted: Friday, September 23, 2022
The anti-CD20–monomethyl auristatin E (MMAE) antibody-drug conjugate TRS005 appears to be well tolerated and may improve clinical outcomes for some patients with relapsed or refractory B-cell non-Hodgkin lymphoma, according to the preliminary results from a phase I study conducted at 11 centers in China. These findings were presented by Yuan-Kai Shi, MD, of the Chinese Academy of Medical Sciences, Beijing, during the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract 618O).
“TRS005...targets CD20-positive tumor cells to deliver MMAE, a highly toxic antimitotic agent, into the cells via receptor-mediated endocytosis,” stated the study investigators.
Patients with relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma (n = 40) received intravenous TRS005 on the first day of each 21-day cycle for six cycles. The dose-escalation phase included seven cohorts ranging from 01.mg/kg to 2.3 mg/kg. Dose-limiting toxicity was observed in the 2.1-mg/kg cohort because of liver damage. Treatment-related adverse events were observed in 78% of patients, 34.1% of which were grade 3 or higher, and neutropenia was the most common (10.1%).
At the data cutoff date, the overall response rate was 37.1%, and the disease control rate was 60%. The overall response and disease control rates across dose cohorts were at least 42.9% and at least 57.1%, respectively, apart from the 1.0-mg/kg dose (16.7% and 16.7%). The highest dose (1.8 mg/kg) yielded an overall response rate of 50% and a disease control rate of 100% in four patients. Across histology subtypes, the overall response and disease control rates in patients with follicular lymphoma were 21.4% and 42.9%, respectively, and in diffuse large B-cell lymphoma, 46.7% and 66.7%, respectively. For patients with mantle cell lymphoma and marginal zone lymphoma, the overall response and disease control rates were both 100%.
Disclosure: The study authors reported no conflicts of interest.